Relmada Therapeutics, Inc. RLMD Operating Loss Carryforward Limitations On Use
Operating Loss Carryforward Limitations On Use at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rlmd:OperatingLossCarryforwardLimitationsOnUse.
The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s operating loss carryforward limitations on use.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s operating loss carryforward limitations on use?
- Relmada Therapeutics, Inc. (RLMD) reported operating loss carryforward limitations on use of $61.6M in Q4 2025.
- What does operating loss carryforward limitations on use mean?
- Reflects the constraints imposed on the utilization of net operating loss carryforwards to offset future taxable income. This is often driven by regulatory thresholds or ownership changes that restrict the company's ability to reduce its tax burden.